MX2022016587A - Bioconjugado tetravalente de shigella (shigella4v). - Google Patents

Bioconjugado tetravalente de shigella (shigella4v).

Info

Publication number
MX2022016587A
MX2022016587A MX2022016587A MX2022016587A MX2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A MX 2022016587 A MX2022016587 A MX 2022016587A
Authority
MX
Mexico
Prior art keywords
shigella
tetravalent
shigella4v
bioconjugate
bioconjugates
Prior art date
Application number
MX2022016587A
Other languages
English (en)
Spanish (es)
Inventor
Stefan Jochen Kemmler
Martin Edward Braun
Rainer Follador
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2022016587A publication Critical patent/MX2022016587A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2022016587A 2020-06-18 2021-06-17 Bioconjugado tetravalente de shigella (shigella4v). MX2022016587A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063040844P 2020-06-18 2020-06-18
US202063043883P 2020-06-25 2020-06-25
EP20182138 2020-06-25
EP20182139 2020-06-25
PCT/IB2021/055361 WO2021255684A1 (en) 2020-06-18 2021-06-17 Shigella-tetravalent (shigella4v) bioconjugate

Publications (1)

Publication Number Publication Date
MX2022016587A true MX2022016587A (es) 2023-02-01

Family

ID=76502778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016587A MX2022016587A (es) 2020-06-18 2021-06-17 Bioconjugado tetravalente de shigella (shigella4v).

Country Status (8)

Country Link
US (1) US20230346902A1 (https=)
EP (1) EP4168040A1 (https=)
JP (1) JP2023530154A (https=)
CN (1) CN115697396A (https=)
BR (1) BR112022024294A2 (https=)
CA (1) CA3185719A1 (https=)
MX (1) MX2022016587A (https=)
WO (1) WO2021255684A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2671709C (en) 2006-12-13 2016-08-16 The Governors Of The University Of Alberta Methods and systems for o-glycosylating proteins
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
EP2501406B8 (en) 2009-11-19 2018-01-24 GlaxoSmithKline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
CN110423716A (zh) * 2012-10-12 2019-11-08 葛兰素史密丝克莱恩生物有限公司 宿主细胞修饰方法
CA2889767C (en) * 2012-11-07 2021-09-21 Glycovaxyn Ag Production of recombinant vaccine in e. coli by enzymatic conjugation
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
ES2672045T3 (es) * 2014-07-25 2018-06-12 Biosynth S.R.L. Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
EP3310381B1 (en) * 2015-06-16 2023-06-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition

Also Published As

Publication number Publication date
WO2021255684A1 (en) 2021-12-23
EP4168040A1 (en) 2023-04-26
CN115697396A (zh) 2023-02-03
BR112022024294A2 (pt) 2023-02-28
CA3185719A1 (en) 2021-12-23
US20230346902A1 (en) 2023-11-02
JP2023530154A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
ZA202310611B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GEP20247633B (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CY1111114T1 (el) Ανοσοενισχυμενες αντιγονικες μηνιγγιτιδοκοκκικες συνθεσεις
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
EA035991B9 (ru) Новый полисахарид и его применения
DE60311772D1 (de) Vorrichtung zur herstellung von infusionsgetränken
DE602006017225D1 (de) Erbsenproteinzusammensetzung
NO20005672L (no) Svekkede Salmonella-mutanter som konstitutivt uttrykker Vi- antigenet
MX2019013605A (es) Material botanico homogeneizado que comprende un modificador de ph basico.
CY1115710T1 (el) Ρευστο παρασκευασμα που περιλαμβανει ενα συμπλοκο πιμοβενδανης και κυκλοδεξτρινης
TR200200065T2 (tr) Dış salgılama bozukluklarının tedavisi için terkip
AR118389A1 (es) Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
BG107220A (en) Antitumoral ecteinascudin derivatives
ZA202101663B (en) Purified capsular polysaccharides of streptococcus pneumoniae
MX2024008039A (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y usos de los mismos.
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
MX2022015734A (es) Proteinas de exotoxina a modificadas.
MX2022005452A (es) Conjugados farmaco-anticuerpo dirigidos a la claudina 18.2.
AR105010A1 (es) Composiciones inmunógenas
BR0113915A (pt) Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
MX2023013665A (es) Polipeptidos del sars-cov-2.
MX2022003243A (es) Conjugados anticuerpo-farmaco anti-ptcra y usos de los mismos.
MX2022016587A (es) Bioconjugado tetravalente de shigella (shigella4v).
MA45283B1 (fr) Une composition de multivalent pneumococcal la protéine de polysaccaride-transporteur capsulaire se conjugue et utilisez de cela